Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you treat a completely resected Stage IA NSCLC EGFR exon 19 with adjuvant osimertinib alone omitting chemotherapy?
Related Questions
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
How would you manage a patient with stage IV EGFR L858R mutation but with a debilitating drug rash from osimertinib?
How do you handle Grade 3-4 standard infusion reactions with Amivantamab?
In patients with driver mutation positive NSCLC who have progressed on targeted therapy and are planned for chemotherapy as the next line of treatment, for which driver alterations do you add in IO and which do you omit IO?
How would you treat Stage III unresectable adenocarcinoma of the lung with a BRAF-V600E mutation?
What are your top takeaways from ESMO 2023?
What is the role for molecular agents alone for medically inoperable NSCLC who is not a good candidate for chemoRT?
Would you consider "consolidation" chemoradiotherapy for a Stage III NSCLC that was initially felt to be too extensive for definitive intent radiotherapy who later experiences a radiographic complete response to carboplatin, paclitaxel, and pembrolizumab?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
